<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Learn Mem</journal-id>
<journal-id journal-id-type="iso-abbrev">Learn. Mem</journal-id>
<journal-id journal-id-type="publisher-id">learnmem</journal-id>
<journal-title-group>
<journal-title>Learning &amp; Memory</journal-title>
</journal-title-group>
<issn pub-type="ppub">1072-0502</issn>
<issn pub-type="epub">1549-5485</issn>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32817301</article-id>
<article-id pub-id-type="pmc">7433657</article-id>
<article-id pub-id-type="doi">10.1101/lm.051201.119</article-id>
<article-id pub-id-type="publisher-id">LM051201Sch</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of a TrkB agonist on spatial and motor learning in the <italic>Ube3a</italic> mouse model of Angelman syndrome</article-title>
<alt-title alt-title-type="left-running"><italic>TrkB agonist in</italic> Ube3a <italic>Angelman mice</italic></alt-title>
<alt-title alt-title-type="right-running"><italic>TrkB agonist in</italic> Ube3a <italic>Angelman mice</italic></alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Schultz</surname>
<given-names>Maria N.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Crawley</surname>
<given-names>Jacqueline N.</given-names>
</name>
</contrib>
</contrib-group>
<aff>MIND Institute, Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, California 95821, USA</aff>
<author-notes>
<corresp>Corresponding author: <email>crawley@ucdavis.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<month>9</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<month>9</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>27</volume>
<issue>9</issue>
<fpage>346</fpage>
<lpage>354</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>
<ext-link ext-link-type="uri" xlink:href="http://www.learnmem.org/site/misc/terms.xhtml">Â© 2020 Schultz and Crawley; Published by Cold Spring Harbor Laboratory Press</ext-link>
</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article, published in <italic>Learning &amp; Memory</italic>, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="LM051201Sch.pdf"></self-uri>
<abstract>
<p>Angelman syndrome is a rare neurodevelopmental disorder caused by a mutation in the maternal allele of the gene <italic>Ube3a</italic>. The primary symptoms of Angelman syndrome are severe cognitive deficits, impaired motor functions, and speech disabilities. Analogous phenotypes have been detected in young adult <italic>Ube3a</italic> mice. Here, we investigate cognitive phenotypes of <italic>Ube3a</italic> mice as compared to wild-type littermate controls at an older adult age. Water maze spatial learning, swim speed, and rotarod motor coordination and balance were impaired at 6 mo of age, as predicted. Based on previous findings of reduced brain-derived neurotrophic factor in <italic>Ube3a</italic> mice, a novel therapeutic target, the TrkB agonist 7,8-DHF, was interrogated. Semichronic daily treatment with 7,8-DHF, 5 mg/kg i.p., did not significantly improve the impairments in performance during the acquisition of the water maze hidden platform location in <italic>Ube3a</italic> mice, after training with either massed or spaced trials, and had no effect on the swim speed and rotarod deficits. Robust behavioral phenotypes in middle-aged <italic>Ube3a</italic> mice appear to result from continued motor decline. Our results suggest that motor deficits could offer useful outcome measures for preclinical testing of many pharmacological targets, with the goal of reducing symptoms in adults with Angelman syndrome.</p>
</abstract>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap>
<institution>The National Institutes fof Health </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>R01 NS085709</award-id>
<award-id>U54 HD079125</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="9"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>